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Abstract
Background: To examine common antimicrobial regimens used in eradicating certain nosocomial Gram-negative 
pathogens and determine which ones are likely to be the most suitable as empirical choices in Shenyang, China.
Methods: A 5000-subject Monte Carlo simulation was conducted to determine the cumulative fraction of response 
(CFR) for meropenem, imipenem, cefepime, piperacillin/tazobactam and levofloxacin against Escherichia coli, Klebsiella 
pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Pseudomonas aeruginosa collected in 2006 and 2007 
from Shenyang.
Results: Meropenem and imipenem had the highest CFRs against the Enterobacteriaceae (97%-100%), followed by 
cefepime. No antibiotic simulated regimen achieved optimal CFR against P. aeruginosa and A. baumannii. Piperacillin/
tazobactam dosed at 4.5 g q8h achieved the lowest CFR against all bacteria.
Conclusions: This study suggests that the carbapenems provide the greatest likelihood of clinical success for the 
Enterobacteriaceae, and combination therapy might be needed when choosing empirical therapy, especially when A. 
baumannii or P. aeruginosa are suspected.
Background
The rapid increase in the prevalence of multidrug resis-
tant microorganisms has threatened the physician's abil-
ity to treat serious infections. Since there are a limited
number of antimicrobials available that can treat multi-
drug resistant gram-negative bacteria such as Enterobac-
teriaceae harboring extended-spectrum β-lactamases
(ESBLs), multidrug-resistant P. aeruginosa and A. bau-
mannii, the best approach to combating resistance and
providing effective therapy is optimizing the use of cur-
rently available antimicrobial agents.
Antibiotic surveillance studies lack consideration of
pharmacokinetics and provide little information about
optimal dosing. The consideration of minimum inhibi-
tory concentration (MIC) distribution, antibiotic regimen
and pharmacokinetic parameter derived from human
studies via application of pharmacokinetic/pharmacody-
namic (PK/PD) models with Monte Carlo simulation
offers a more useful tool for clinicians to predict success-
ful outcomes [1].
Given that Gram-negative bacteria resistance is
increasing rapidly and varies considerably by geographi-
cal location in China, location-specific information on
pharmacokinetic-pharmacodynamic profiling of com-
mon antibiotics (such as meropenem, imipenem,
cefepime, piperacillin/tazobactam and levofloxacin)
against problem pathogens is of particular concern, thus
we conducted this study to assess common antibiotic reg-
imens utilized in Shenyang in order to provide insight
into the appropriate antibiotic and dosing options for the
empiric therapy of common nosocomial pathogens.
Methods
The present study was performed with isolates collected
consecutively during 2006 to 2007 from patients hospital-
ized in The First Hospital of China Medical University,
The Second Hospital of China Medical University, and
Provincial People Hospital in Shenyang. Included bacte-
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rial strains were isolates of non-duplicate E. coli (n = 414),
K. pneumoniae (n = 236), E. cloacae (n = 40), P. aerugi-
nosa (n = 281) and A. baumannii (n = 115). Identification
of the species level was performed by each laboratory of
the participant Hospital with either conventional bio-
chemical methodology or an automated system (Vitek 2,
bioMérieux, France).
The MIC data of meropenem, imipenem, cefepime,
piperacillin/tazobactam and levofloxacin against these
bacteria were determined by the agar dilution method at
Department of Laboratory Medicine, The First Hospital
of China Medical University according to Clinical and
Laboratory Standards Institute guidelines (Table 1). Con-
trol strains of E. coli (ATCC 25922) and P. aeruginosa
(ATCC 27853) were run with each set of MIC determina-
tions.
The percent of the dosing interval during which free
(i.e. unbound) drug was above the MIC (% f T > MIC) was
selected as the pharmacodynamic exposure of interest.
The following antibiotic regimens were chosen based on
the most common regimens used in Shenyang to treat
these suspected pathogens modeled as 30-min intrave-
nous (i.v.) infusions: meropenem 0.5 g every 6 hours
(q6h), 1 g q8h, and 1 g q12h; imipenem 0.5 g q6h, 1 g q8h
and 1 g q12h; cefepime 1 g q8h and 2 g q8h and 2 g q12h;
and piperacillin/tazobactam 4.5 g q8h. A one-compart-
ment i.v. -infusion equation was used to calculate % f T >
MIC for the β - lactams at steady state as previously
described [2]:
where Ln is the natural logarithm, f is the fraction of
unbound drug, Vd is the volume of distribution in liters at
steady state, CLT is the total body clearance in liters per
hour, and DI is the dosing interval for the regimen.
Pharmacokinetic-pharmacodynamic exposures for
l ev o fl o x a c i n  w e r e  m e a s u r e d  b y  c a l c u l a t i o n  o f  t h e  t o t a l
drug 24-h area under the concentration-time curve
(AUC) to MIC ratio (AUC/MIC). Total drug AUC for
levofloxacin regimens (levofloxacin 0.5 every 24 h) were
calculated by dividing the daily dose by total plasma
clearance
Pharmacokinetic data were obtained from previously
published studies with healthy volunteers using previ-
ously described selection criteria [2,3]. Table 2 gives the
mean and standard deviation for the total body clearance
( t o t a l  b o d y  p l a s m a  c l e a r a n c e  w a s  c a l c u l a t e d  a s  C L  =
dose/AUC, AUC was determined by the trapezoidal rule
and was extrapolated to infinity [4]) in liters per hour
resulting assumptions used to model total plasma clear-
ance (CLT), volume of the central compartment (Vd),
fraction unbound and AUC0-24.
A 5000-patient Monte Carlo simulation (Crystal Ball
2000; Decisioneering Inc., Denver, CO) was conducted to
calculate estimates of % f T > MIC or AUC/MIC ratio for
each antibiotic dosage regimen and bacterial population
combination. Five thousand estimates of pharmacody-
namic exposure were generated for each antibiotic regi-
men against each bacterial population using values for
CLT, Vd, f, and MIC based on probability distributions, as
previously described [2]. During simulations, pharma-
cokinetic parameters were assumed to follow log-Gauss-
ian distributions and the fraction unbound f followed a
uniform distribution. Discrete MIC distributions were
built for each population of bacteria based on the MIC
frequencies, whereby the percentage of bacteria for which
each MIC applies is treated as a frequency and values in
between the MIC do not exist. The cumulative fraction of
response (CFR) was calculated over the MIC distribu-
tions using weighted summation [5]. For comparative
purpose, bactericidal pharmacodynamic breakpoints
were defined as 40% f T > MIC for meropenem and imi-
penem, 50% f T > MIC for cefepime, and piperacillin-
tazobactam, and a total drug AUC/MIC ≥ 125 for levo-
floxacin. A regimen that achieved > 90% CFR against a
population of organisms was considered optimal [6].
Results
The CFRs for each antibiotic dosage regimen against each
population of bacteria are given in Table 3. Overall, CFRs
were highest against the Enterobacteriaceae, followed by
P. aeruginosa and then A. baumannii.
Against the Enterobacteriaceae, meropenem and imi-
penem at all simulated dosage regimens achieved the
highest CFRs. Because lower doses of meropenem and
imipenem (0.5 g q8h or q6h) by the standard 30-minute
infusion obtained 97%-100% CFR against Enterobacteri-
aceae, increasing the dose of meropenem to 1 g q8h had
no clinical significance for these three species (98%-100%
CFR) (Table 3).
Against E. coli, cefepime also fared well, with higher
CFRs (95%) than the optimal CFR (90%) at the simulated
regimen of 2 g q8h and slightly lower CFRs (90%) at the
lower dose of 1 g q8h and 2 g q12h. Piperacillin/tazobac-
tam dosed at 4.5 g q8h achieved the lowest CFR against
all bacteria. Particularly, levofloxacin regimens achieved
significantly less exposure against E. coli (30%) than E.
cloacae (68%) and K. pneumoniae (44%).
No antibiotic simulated regimen achieved high enough
CFRs against the nonfermenters to warrant its use empir-
ically as monotherapy. Against P. aeruginosa and A. bau-
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Table 1: MIC distributions for various antimicrobials tested from Shenyang in China
Species(no.) or antibiotic %S % of isolates susceptible at MIC(μg/ml) MIC50 MIC90 MIC range
0.006 0.01 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256
E.coli (414)
MEM 99.8 94.4 1.7 1.5 1 0.5 0.7 0 0 0.2 0 0 0 0 0 0 0 0.03 0.032 .03 - 8
IPM 99.8 17.9 11.5 21.5 43.3 4.6 0.5 0.5 0 0.2 0 0 0 0 0 0 0 0.125 0.25 .03 - 16
FEP 69.4 12.7 1.3 2.5 4.1 16.7 5.3 2.7 9 15.3 12.1 8.3 4.4 2.4 1.7 1.5 0 4 32 .03 - 512
TZP 70.5 0.5 0 0 0.2 0.5 1 7.9 19 24.1 16.9 10.2 9.9 3 2.2 4.2 0 8 64 .03 - 512
LVX 30.8 6.8 3 1.2 8.2 5.7 5 1 7.4 18.6 23.3 14.4 5 0.2 0.2 0 0 8 32 .03 - 256
K.pneumoniae (236)
MEM 99.6 4.7 50.4 34.8 4.9 1.8 0.4 0.9 1.3 0.4 0 0.4 0 0 0 0 0 0.03 0.125 .015 - 16
IPM 97.8 0 0 0.6 13.1 42.2 15.5 2.5 14.9 11.2 0 0 0 0 0 0 0 0.25 2 .03 - 32
FEP 62.3 0 3 13 15.2 3.9 3.5 3.5 7.8 8.2 4.3 10.4 9.5 4.3 4.3 1.3 7.8 4 128 .03 - 512
TZP 44.6 0 0 0 0 0 0 0 1.4 11.6 19.2 12.5 21 18.3 6.7 7.1 2.2 32 128 2 - 512
LVX 64.5 0 23.8 7.9 2.6 3.9 4.8 11 11 4.8 7 8.8 7.5 5.7 1.3 0.4 0 1 32 .03 - 256
E.cloacae (40)
M E M 9 7 . 5 0 09 00 0 5 2 . 5 0000 2 . 5 00000 . 0 3 0 . 0 3 2. 0 3  -  1 6
IPM 97.5 0 0 12.5 50 0 17.5 7.5 10 0 0 2.5 0 0 0 0 0 0.06 1 .03 - 8
FEP 67.5 0 0 27.5 7.5 7.5 2.5 0 10 2.5 7.5 2.5 10 12.5 5 2.5 2.5 1 32 .03 - 256
TZP 60 0 0 0 0 0 0 0 2.5 10 22.5 7.5 17.5 7.5 2.5 5 25 16 256 1 - 512
LVX 70 0 0 57.5 7.5 0 2.5 0 2.5 0 2.5 2.5 7.5 15 2.5 0 0 0.03 32 .03 - 64
P.aeruginosa (281)
MEM 56.8 0 0 1.5 4.1 7 10 13 9.2 4.4 7.4 12.5 20.3 4.4 3 2.9 0 4 32 .03 - 128
IPM 46.5 0 0 1.1 1.1 0.4 0.7 4.1 18 10 11.4 14.8 8.5 19.9 5.2 3 2.1 8 64 .03 - 512
FEP 45.9 0 0 1.5 0 0 0 1.1 6.3 8.5 9.6 18.9 20.7 11.9 8.1 7.8 5.6 16 128 .03 - 512
TZP 43.7 0 0 0.4 0 0 0 0.7 0 1.5 3.7 12.2 8.9 6.7 9.6 10 46 128 256 .03 - 512
LVX 56.1 0 0 5.9 1.1 9.6 15.1 8.9 11 4.4 7.7 14.8 11.4 5.5 2.6 1.5 0.4 1 16 .03 - 256
A.baumannii (115)
MEM 37.8 0 0 4.2 7.2 5.2 6.1 7.1 6.1 1 1 2 5.1 30.6 11.2 12.2 1 32 128 .03 - 256
IPM 35.7 0 0 2 7.1 8.2 3.1 4.1 6.1 4.1 1 5.1 8.2 23.5 21.4 5.1 1 32 64 .03 - 256
FEP 19.8 0 0 0 0 0 1.9 0 2.7 3.6 8.1 3.6 16.2 7.2 9 22.5 25 64 256 .25 - 512
TZP 17.3 0 0 2 0 0 1.1 0 0 2 0 8.2 4.1 0 1 3.1 79 256 256 .03 - 512
LVX 48.7 0 0 14.8 0.9 2.6 0.9 3.5 3.5 22.6 27 12.2 7 5 0 0 0 4 16 .03 - 32
MEM Meropenem; IPM Imipenem; FEP Cefepime; TZP Piperacillin/tazobactam; LVX LevofloxacinChu et al. BMC Infectious Diseases 2010, 10:171
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mannii, all antibiotic regimens achieved very low CFRs (≤
60%) with the exception of cefepime dosed at 2000 mg
every 8 hours against P. aeruginosa (68%).
Discussion
Our simulations demonstrated that meropenem and imi-
penem achieved a high likelihood of bactericidal activity
against the Enterobacteriaceae, with CFRs close to 100%.
These findings support other studies [2,7,8] indicating
that for mild to moderate infections caused by pathogens
with inherently low MICs, such as the Enterobacteri-
aceae, meropenem and imipenem 0.5 g q8h as a 30-min-
ute infusion may be as effective as standard therapy (1 g,
q8h), resulting in decreased costs; whereas for treatment
of more severe infections and higher risk of P. aeruginosa
or other antibiotic-resistant, gram-negative pathogens,
meropenem at higher dose (2 g, q8h) would optimize the
pharmacodynamic parameter of %T > MIC.
Additionally, larger or more frequent doses of antibiotic
against the nonfermenters resulted in increases in the
CFRs, but not enough to justify the use of any of these
agents empirically as monotherapy. This may have clini-
cal relevance, since dosage increase is a common
response to try to curb resistance. The data shown here
clearly demonstrate that for the regimens evaluated, dos-
age increase would not be a good option for empiric
treatment. Instead, because no single regimen had high
CFR against A. baumannii and P. aeruginosa, the use of
empiric combination therapy to treat these pathogens
may be worthwhile. A recent study demonstrated that the
use of combination antimicrobial therapy for the P. aerug-
inosa bacteremia resulted in an improvement in 30-day
survival; at least until the antibiotic susceptibility results
were available to help guide therapy [8].
In addition, being different from other study [9], the
results of these simulations are strongly supported by the
dramatically increasing resistance emerging in carbap-
enem-resistant A. baumannii in Shenyang (China), with
only 38%- 36% susceptible to meropenem and imipenem
respectively (data not shown). Other study suggests that
the carbapenemase blaOXA-23 and the AdeABC efflux
pump were the importance mechanism of imipenem-
Table 2: Assumptions for pharmacokinetic parameters used during simulations
Antibiotic Pharmacokinetic (mean ± SD) Reference
CLT (liters/h) Vd (liters) Fraction unbound (%) AUC0-24
Meropenem 14.4 ± 1.8 18.6 ± 3.0 0.85-0.98 - 2
Imipenem 10.5 ± 1.4 15.3 ± 3.3 0.80-0.95 - 2
Cefepime 5.3 ± 0.6 13.6 ± 2.4 0.8-0.9 - 2
Piperacillin/tazobactam 10.9 ± 1.2 11.9 ± 1.7 0.65-0.75 - 2
Levofloxacin - - - 48 ± 8 3
Table 3: Bactericidal cumulative fractions of response (CFRs) for antibiotic dosage regimens against Escherichia coli, 
Klebsiella pneumoniae, Enterobacter cloacae, Pseudomonas aeruginosa and Acinetobacter baumannii collected from 
Shenyang in China
Regimen Bactericidal CFR (%)
E. coli K. pneumoniae E. cloacae P. aeruginosa A. baumannii
Meropenem 0.5 g q6h 100 100 100 52 59
Meropenem 0.5 g q8h 100 100 97 46 59
Meropenem 1 g q8h 100 100 100 54 59
Imipenem 0.5 g q6h 100 99 97 45 36
Imipenem 0.5 g q8h 100 97 97 36 34
Imipenem 1 g q8h 100 99 98 49 37
Cefepime 1 g q8h 90 73 68 48 22
Cefepime 2 g q8h 95 83 78 68 37
Cefepime 2 g q12h 90 74 68 45 22
Piperacillin/tazobactam 4.5 g q8h 71 33 34 11 8
Levofloxacin 0.5 g every 24 h 30 44 68 33 19Chu et al. BMC Infectious Diseases 2010, 10:171
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resistance in this region (this was done in a separate proj-
ect). It alludes to the fact that it is critical to know local
trends in resistance and MIC distributions, since infor-
mation from elsewhere (even within the same country)
could lead one to utilize less optimal dosing regimens.
Ideally, the use of hospital- or unit-specific (i.e. ICU) MIC
distributions in those Monte Carlo simulations would
provide the most reliable data for designing empirical
dosing regimens [10].
There are a few issues that require discussion. With
regard to the pharmacokinetic data, the parameters cho-
sen were selected from healthy adults rather than
patients. This is due to the lack of comparable pharma-
cokinetic trials of all these agents in the same patient
population; we utilized healthy volunteer data to make a
conservative estimate, similar to other studies [2,9]. Addi-
tionally, some studies showed that the pharmacodynamic
target attainment calculated with healthy subject phar-
macokinetic data was predictive of patient target attain-
ment for the β-lactams [11].
Additional limitations of the study are that it does not
look at the new carbapenem, doripenem, and neither
does it evaluate prolonged nor continuous infusion regi-
mens.
Conclusions
This pharmacokinetic-pharmacodynamic simulation
provides a useful tool that complements susceptibility
data to help in the selection of appropriate empirical anti-
biotic therapy on the regional level. It suggests that the
carbapenems, and specifically meropenem, remain the
most potent agents for the Enterobacteriaceae, and owing
to high antibiotic MICs among many Gram-negative rods
in Shenyang, combination therapy might be needed when
choosing empirical therapy, especially when A. bauman-
nii or P. aeruginosa are suspected.
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